Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    Peanut Reactivity Reduced by Oral Tolerance in an anti-IgE Clinical
Show Display Options
Rank Status Study
1 Active, not recruiting Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
Conditions: Peanut Allergy;   Food Allergy
Interventions: Drug: Omalizumab;   Drug: placebo

Indicates status has not been verified in more than two years